| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H13N3 |
| Molecular Weight | 211.2624 |
| Optical Activity | NONE |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1[C@H]2CNC[C@@H]1C3=CC4=C(C=C23)N=CC=N4
InChI
InChIKey=JQSHBVHOMNKWFT-DTORHVGOSA-N
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+
| Molecular Formula | C13H13N3 |
| Molecular Weight | 211.2624 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Varenicline is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain. Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectiviyty for this receptor subclass, relative to other nicotinic receptors (>500-fold alpha-3 beta-4, >3500-fold alpha-7, >20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (>2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms. Varenicline is sold under the trade name Chantix and Champix, it is indicated for use as an aid to smoking cessation treatment.
CNS Activity
Originator
Approval Year
AUC
T1/2
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
Begin CHANTIX (Varenicline) dosing one week before the date set by the patient to
stop smoking. Alternatively, the patient can begin CHANTIX dosing and
then quit smoking between days 8 and 35 of treatment. (2.1)
• Starting week: 0.5 mg once daily on days 1-3 and 0.5 mg twice daily on
days 4-7. (2.1)
• Continuing Weeks: 1 mg twice daily for a total of 12 weeks. (2.1)
• An additional 12 weeks of treatment is recommended for successful
quitters to increase likelihood of long-term abstinence. (2.1)
• Consider a gradual approach to quitting smoking with CHANTIX for
patients who are sure that they are not able or willing to quit abruptly.
Patients should begin CHANTIX dosing and reduce smoking by 50% from
baseline within the first four weeks, by an additional 50% in the next four
weeks, and continue reducing with the goal of reaching complete
abstinence by 12 weeks. Continue treatment for an additional 12 weeks,
for a total of 24 weeks. (2.1)
CHANTIX should be taken orally after eating and with a full glass of water.
Route of Administration:
Oral
